janus kinase 2

Summary

Summary: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.

Top Publications

  1. Zhang Y, He X, Wu X, Lei M, Wei Z, Zhang X, et al. Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease. Cell Death Dis. 2017;8:e2611 pubmed publisher
    ..NF-?B was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated ..
  2. Babon J, Lucet I, Murphy J, Nicola N, Varghese L. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1-13 pubmed publisher
    ..These recent studies highlight the diversity of regulatory mechanisms utilized by the JAK family to maintain signalling fidelity, and suggest alternative therapeutic strategies to complement existing ATP-competitive kinase inhibitors. ..
  3. Yoshimi A, Balasis M, Vedder A, Feldman K, Ma Y, Zhang H, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017;130:397-407 pubmed publisher
    ..These data reveal that NSGS mice support the development of CMML and JMML disease-initiating and mature leukemic cells in vivo, allowing creation of genetically accurate preclinical models of these disorders. ..
  4. Zhang Z, Yang C, Dai X, Ao Y, Li Y. Inhibitory effect of trans-caryophyllene (TC) on leukocyte-endothelial attachment. Toxicol Appl Pharmacol. 2017;329:326-333 pubmed publisher
    ..Our results suggest that TC might have a capacity to suppress the development of atherosclerosis. ..
  5. Wu K, Huang J, Zhong H, Dong Z, Vellaisamy K, Lu J, et al. A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. PLoS ONE. 2017;12:e0177123 pubmed publisher
    ..Finally, compound 1 induced apoptosis in 80% of treated melanoma cells. To our knowledge, compound 1 is the first amentoflavone-based JAK2 inhibitor to be investigated for use as an anti-melanoma agent. ..
  6. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica. 2010;95:518-9 pubmed publisher
  7. Zhang Y, Liang R, Chen C, Mallano T, Dees C, Distler A, et al. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann Rheum Dis. 2017;76:1467-1475 pubmed publisher
    b>Janus kinase 2 (JAK2) has recently been described as a novel downstream mediator of the pro-fibrotic effects of transforming growth factor-?...
  8. Eder Azanza L, Evans P, Wickham C, Akiki S, Vizmanos J, Chase A, et al. Constitutional genetic association with CALR mutations?. Leukemia. 2015;29:2410-1 pubmed publisher
  9. Xiao J, Gong Y, Chen Y, Yu D, Wang X, Zhang X, et al. IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. Am J Physiol Renal Physiol. 2017;313:F310-F318 pubmed publisher
    ..IL-6 may serve as a novel therapeutic target for preventing EMT, and preservation of the peritoneal membrane may arise from these studies. ..

More Information

Publications98

  1. Kuriakose E, Gjoni S, Wang Y, Baumann R, Jones A, Cross N, et al. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica. 2013;98:e135-7 pubmed publisher
  2. Singh S, Chouhan S, Mohammad N, Bhat M. Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 2017;591:1371-1382 pubmed publisher
    ..Interestingly, we observe that resistin-exposed cells survive 5-fluorouracil treatment because of a decrease in drug uptake due to the arrest of cells in G1 phase. ..
  3. Tefferi A, Levitt R, Lasho T, Knudson R, Ketterling R. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2010;85:86-7 pubmed publisher
  4. Lv K, Jiang J, Donaghy R, Riling C, Cheng Y, Chandra V, et al. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev. 2017;31:1007-1023 pubmed publisher
    b>Janus kinase 2 (JAK2) is a central kinase in hematopoietic stem/progenitor cells (HSPCs), and its uncontrolled activation is a prominent oncogenic driver of hematopoietic neoplasms...
  5. Guo B, Allcock R, Mirzai B, Malherbe J, Choudry F, Frontini M, et al. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations. Am J Pathol. 2017;187:1512-1522 pubmed publisher
    ..These findings show that genomic abnormalities are present in megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow fibrosis. ..
  6. Tada S, Okuno T, Hitoshi Y, Yasui T, Honorat J, Takata K, et al. Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11:179 pubmed publisher
    ..b>Janus kinase 2 (JAK2), one of the key molecules in inflammation, transduces signals downstream of various inflammatory ..
  7. Bar Natan M, Nelson E, Walker S, Kuang Y, Distel R, Frank D. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia. 2012;26:1407-10 pubmed publisher
  8. Grisouard J, Hao Shen H, Dirnhofer S, Wagner K, Skoda R. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014;99:e52-4 pubmed publisher
  9. Lim K, Chang Y, Gon Shen Chen C, Lin H, Wang W, Chiang Y, et al. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J. 2015;5:e295 pubmed publisher
  10. Kantarjian H, Schiffer C, Burnett A. Hematologic malignancies: where do we stand in 2011?. J Clin Oncol. 2011;29:473-4 pubmed publisher
  11. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192:719-28 pubmed
    ..Thus, Stat5a is essential for at least certain effects of FL. Moreover, our data confirm that Stat5a and Stat5b are not redundant, but rather are at least partially distinctive in their function. ..
  12. Shimizu D, Inokawa Y, Sonohara F, Inaoka K, Nomoto S. Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review). Oncol Rep. 2017;37:2527-2542 pubmed publisher
    ..In the present study, we review the currently identified tumor factors and background liver factors from a molecular biological viewpoint and also introduce our combination array analysis. ..
  13. Sato N, Morishita R. Plasma a?: a possible missing link between Alzheimer disease and diabetes. Diabetes. 2013;62:1005-6 pubmed publisher
  14. Sadras T, Heatley S, Kok C, McClure B, Yeung D, Hughes T, et al. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genet. 2017;216-217:86-90 pubmed publisher
  15. Cai H, Yao Z, Li W. IRF-5 accelerates leukocyte adhesion to endothelial cells in ischemia-reperfusion injury through regulating the transcription of VCAM-1. Biochem Biophys Res Commun. 2017;492:192-198 pubmed publisher
    ..In conclusion, we identify IRF-5 as a new regulator and thus a therapeutic target in IRI-driven cardiovascular pathologies. ..
  16. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369-70 pubmed publisher
  17. Murphy P, McPherson S, Langabeer S. Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha. Ann Hematol. 2011;90:233-4 pubmed publisher
  18. Rao N, Butcher C, Lewis I, Ross D, Melo J, Scott H, et al. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol. 2012;156:268-70 pubmed publisher
  19. Kim E, Cheng Y, Bolton Gillespie E, Cai X, Ma C, Tarangelo A, et al. Rb family proteins enforce the homeostasis of quiescent hematopoietic stem cells by repressing Socs3 expression. J Exp Med. 2017;214:1901-1912 pubmed publisher
    ..Therefore, Rb proteins act as a central hub of quiescence and homeostasis by coordinating the regulation of both cell cycle and Jak2 signaling in HSCs. ..
  20. Meyer S. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017;31:627-642 pubmed publisher
    ..Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors. Additional combined therapy approaches are currently being evaluated. ..
  21. Huang C, Chen Y, Liu J, Ho H, Li C, Chen C. JAK2V617F mutation in immune thrombocytopenia. Thromb Res. 2016;144:149-51 pubmed publisher
  22. Sheikholeslami A, Nabiuni M, Arefian E. Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590. Tumour Biol. 2017;39:1010428317697570 pubmed publisher
    ..Apparently, some microRNAs can be good candidates for novel treatments of cancer. Although miR-590 showed good results in this study, further studies are required to investigate the role of miR-590 in breast cancer therapy. ..
  23. Hao W, Wang J, Zhang Y, Wang Y, Sun L, Han W. Leptin positively regulates MUC5AC production and secretion induced by interleukin-13 in human bronchial epithelial cells. Biochem Biophys Res Commun. 2017;493:979-984 pubmed publisher
  24. Kiladjian J, Masse A, Cassinat B, Mokrani H, Teyssandier I, Le Couedic J, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519-23 pubmed publisher
  25. Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, et al. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18-23 pubmed publisher
    ..Our data indicate that older age and high JAK2V617 allele burden are major determinants of inflammation in PMF, and are associated with disease progression. ..
  26. Lamere S, Thompson R, Meng X, Komori H, Mark A, Salomon D. H3K27 Methylation Dynamics during CD4 T Cell Activation: Regulation of JAK/STAT and IL12RB2 Expression by JMJD3. J Immunol. 2017;199:3158-3175 pubmed publisher
    ..Our results show that H3K27me3 is a dynamic and important epigenetic modification during CD4 T cell activation and that JMJD3-driven H3K27 demethylation is critical for CD4 T cell function. ..
  27. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood. 2017;130:115-125 pubmed publisher
    ..Ruxolitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms. ..
  28. Tiong I, Casolari D, Nguyen T, van Velzen M, Ambler K, D Andrea R, et al. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera. Blood Cancer J. 2016;6:e459 pubmed publisher
  29. Barraco D, Cerquozzi S, Hanson C, Ketterling R, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7:e538 pubmed publisher
  30. Alghamdi T, Majumder S, Thieme K, Batchu S, White K, Liu Y, et al. Janus Kinase 2 Regulates Transcription Factor EB Expression and Autophagy Completion in Glomerular Podocytes. J Am Soc Nephrol. 2017;28:2641-2653 pubmed publisher
    The nonreceptor kinase Janus kinase 2 (JAK2) has garnered attention as a promising therapeutic target for the treatment of CKD...
  31. Borriello L, Nakata R, Sheard M, Fernandez G, Sposto R, Malvar J, et al. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017;77:5142-5157 pubmed publisher
    ..These data point to a new type of protumorigenic CAF in the tumor microenvironment of neuroblastoma and to STAT3 and ERK1/2 as mediators of their activity. Cancer Res; 77(18); 5142-57. ©2017 AACR. ..
  32. Alshaker H, Krell J, Frampton A, Waxman J, Blyuss O, Zaikin A, et al. Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway. Breast Cancer Res. 2014;16:426 pubmed publisher
    ..and Src family kinase (SFK) pathways, but not by the major pathways downstream of leptin receptor (LEPR) - janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3)...
  33. Finazzi M, Lussana F, Salmoiraghi S, Spinelli O, Rambaldi A. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. Expert Rev Hematol. 2017;10:627-636 pubmed publisher
    ..Prospective clinical studies are needed to validate the use of this molecular data in the routine clinical practice. ..
  34. Schaub F, Lehmann T, Looser R, Hao Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011;117:2075-6 pubmed publisher
  35. Nagalla S, Bray P. Platelet RNA chips dip into thrombocytosis. Blood. 2010;115:2-3 pubmed publisher
  36. Traer E, Mackenzie R, Snead J, Agarwal A, Eiring A, O Hare T, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. 2012;26:1140-3 pubmed publisher
  37. Fang X, Hong Y, Dai L, Qian Y, Zhu C, Wu B, et al. CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol Carcinog. 2017;56:2434-2445 pubmed publisher
    ..The CRH-induced IL-6 promoted phosphorylation of janus kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3)...
  38. Nanavati A, Patel N, Burke J. Thrombocytosis and coronary occlusion. JACC Cardiovasc Interv. 2012;5:e18-9 pubmed publisher
  39. Maekawa T, Osawa Y, Izumi T, Nagao S, Takano K, Okada Y, et al. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis. Leukemia. 2017;31:2709-2716 pubmed publisher
    ..Our findings confirmed a link between fibrocytes and the TPO/MPL signaling pathway, which could result in a greater understanding of the pathogenesis of MF and lead to the development of novel therapeutic interventions. ..
  40. Yamaji T, Shide K, Kameda T, Sekine M, Kamiunten A, Hidaka T, et al. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Res. 2017;37:3841-3847 pubmed
    In myeloproliferative neoplasms (MPN), Janus kinase 2 (JAK2) is activated by mutations including JAK2V617F (JAK2VF). It is unclear whether JAK kinases [i.e...
  41. Mengdan L, Chen W, Jieyu L, Peiyu J, Fei W, Shengnan L, et al. Low concentration arsenite activated JAK2/STAT3 signal and increased proliferative factor expressions in SV-HUC-1cells after short and long time treatment. Environ Toxicol. 2017;32:2154-2162 pubmed publisher
  42. Fujita H, Hamaki T, Ohwada A, Tomiyama J, Nishimura S. Serum levels of granulocyte colony-stimulating factor in JAK2 V617F-positive vs. negative erythrocytosis. Int J Lab Hematol. 2011;33:e20-1 pubmed publisher
  43. Chan C, Munusamy P, Loke S, Koh G, Wong E, Law H, et al. Identification of Novel Breast Cancer Risk Loci. Cancer Res. 2017;77:5428-5437 pubmed publisher
    ..i>Cancer Res; 77(19); 5428-37. ©2017 AACR. ..
  44. Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, et al. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE. 2017;12:e0181126 pubmed publisher
    ..Hence, Jak1 and Jak2 represent novel therapeutic targets for osteoporosis as well as inflammatory bone diseases including rheumatoid arthritis. ..
  45. Amemiya A, Ito Y, Ishibashi Y, Saito Y, Katagiri S, Suguro T, et al. BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. Rinsho Ketsueki. 2017;58:298-302 pubmed publisher
    ..Five months later, the size of her spleen was reduced. We speculated that translocation of BCR-ABL1 might have occurred in a sub-clone of the JAK2-V617F mutated tumor clone. ..
  46. Yao Xia L, Jing Yan C, Xia Lian T, Ping C, Min Z. The 20kDa and 22kDa forms of human growth hormone (hGH) exhibit different intracellular signalling profiles and properties. Gen Comp Endocrinol. 2017;248:49-54 pubmed publisher
    ..The results revealed that both 22K-GH and 20K-GH can activate Janus kinase 2 (JAK2) and signal transducers and activators of transcription 1, 3 and 5 (STATs 1/3/5)...
  47. Andersen M, Sajid Z, Pedersen R, Gudmand Hoeyer J, Ellervik C, Skov V, et al. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS ONE. 2017;12:e0183620 pubmed publisher
    ..Our findings support intervention at the earliest stage of cancer development to target the malignant clone and dampen concomitant inflammation. ..
  48. Angona A, Fernandez Rodriguez C, Alvarez Larran A, Camacho L, Longarón R, Torres E, et al. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J. 2016;6:e463 pubmed publisher
  49. Tefferi A, Lasho T, Tischer A, Wassie E, Finke C, Belachew A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124:2465-6 pubmed publisher
  50. Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuk F, Wolschke C, et al. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:872-3 pubmed publisher
  51. Dunbar A, Nazir A, Levine R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol. 2017;77:14.40.1-14.40.19 pubmed publisher
    ..2017 by John Wiley & Sons, Inc. ..
  52. Trifa A, Popp R, Cucuianu A, Bănescu C, Tevet M, Martin B, et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015;168:151-3 pubmed publisher
  53. Rumi E, Harutyunyan A, Casetti I, Pietra D, Nivarthi H, Moriggl R, et al. A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014;89:117-8 pubmed publisher
  54. Spolverini A, Pieri L, Guglielmelli P, Pancrazzi A, Fanelli T, Paoli C, et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica. 2013;98:e101-2 pubmed publisher
  55. Godfrey A, Chen E, Massie C, Silber Y, Pagano F, Bellosillo B, et al. STAT1 activation in association with JAK2 exon 12 mutations. Haematologica. 2016;101:e15-9 pubmed publisher
  56. Pardanani A, Lasho T, Finke C, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011;86:701-2 pubmed publisher
  57. Xu Y, Jin J, Xu J, Shao Y, Fan Y. JAK2 variations and functions in lung adenocarcinoma. Tumour Biol. 2017;39:1010428317711140 pubmed publisher
    ..Thus, the up-regulation, mutation and amplification of JAK2 detected in lung adenocarcinoma may participate in lung cancer progression by regulating cancer cells' proliferation, migration and invasion. ..
  58. Bose P, Abou Zahr A, Verstovsek S. Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017;26:723-734 pubmed publisher
    Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis...
  59. Tefferi A, Finke C, Lasho T, Wassie E, Knudson R, Ketterling R, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28:431-3 pubmed publisher
  60. Cappetta M, Perez V, Zubillaga M, Elizondo V, Manrique G, Prosper I, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35:e4-5 pubmed publisher
  61. Chamorro M, Maltaneri R, Vittori D, Nesse A. Protein tyrosine phosphatase 1B (PTP1B) is involved in the defective erythropoietic function of carbamylated erythropoietin. Int J Biochem Cell Biol. 2015;61:63-71 pubmed publisher
  62. Forero Castro M, Robledo C, Benito R, Bodega Mayor I, Rapado I, Hernández Sánchez M, et al. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer. 2017;117:256-265 pubmed publisher
    ..9; P=0.027 and JAK2mut: HR=5.6; P=0.036). TP53mut and JAK2mut are potential biomarkers associated with poor prognosis in B-ALL patients. ..
  63. Couronné L, Lippert E, Andrieux J, Kosmider O, Radford Weiss I, Penther D, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010;24:201-3 pubmed publisher
  64. Sawada T, Arai D, Jing X, Miyajima M, Frank S, Sakaguchi K. Molecular interactions of EphA4, growth hormone receptor, Janus kinase 2, and signal transducer and activator of transcription 5B. PLoS ONE. 2017;12:e0180785 pubmed publisher
    ..In the present study, we report the molecular interactions of EphA4, GH receptor (GHR), Janus kinase 2 (JAK2), and signal transducer and activator of transcription 5B (STAT5B)...
  65. Chang Y, Lin H, Chiang Y, Chen C, Huang L, Wang W, et al. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017;34:83 pubmed publisher
    ..In addition, germline mutations were also found in some cancer-related genes. Copy number changes were rare in this cohort of TN MPNs. In conclusion, both somatic and germline mutations can be detected in TN MPN patients. ..
  66. Khajondetchairit P, Phuangsawai O, Suphakun P, Rattanabunyong S, Choowongkomon K, Gleeson M. Design, synthesis, and evaluation of the anticancer activity of 2-amino-aryl-7-aryl-benzoxazole compounds. Chem Biol Drug Des. 2017;90:987-994 pubmed publisher
    ..A subset of compounds assayed at this target showed IC50 s ranging from 10 to 0.08 ?m; however, no clear correlation between JAK2 potency and A549 cytotoxicity was observed. ..
  67. Kim A, Ulirsch J, Wilmes S, Unal E, Moraga I, Karakukcu M, et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation. Cell. 2017;168:1053-1064.e15 pubmed publisher
    ..Moreover, we have defined a distinct treatable form of anemia through mutation identification and functional studies. ..
  68. Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015;125:3352-3 pubmed publisher
  69. Li Y, Zhang X, Cui L, Chen R, Zhang Y, Zhang C, et al. Salvianolic acids enhance cerebral angiogenesis and neurological recovery by activating JAK2/STAT3 signaling pathway after ischemic stroke in mice. J Neurochem. 2017;143:87-99 pubmed publisher
    ..Previous studies of our laboratory have demonstrated that activating Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway is involved in the ..
  70. Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Tiab M, Ramée J, et al. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood. 2011;118:6468-70 pubmed publisher
  71. Ha J, Jeon D. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol. 2011;86:866-8 pubmed publisher
  72. Lorenzon L, Cippitelli C, Avantifiori R, Uccini S, French D, Torrisi M, et al. Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. J Surg Oncol. 2017;116:184-194 pubmed publisher
    ..Nevertheless, standard pathological features display as the independent variables associated with worse prognosis. ..
  73. Koehler A, Hubert K, Lange T, Siebolts U, Wickenhauser C, Gopalakrishna P, et al. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. Ann Hematol. 2015;94:1929-30 pubmed publisher
  74. Xia X, Xiao C, Shan H. Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway. Eur Rev Med Pharmacol Sci. 2017;21:1248-1253 pubmed
    ..Aging-related proteins P53 and P16 were quantified in Western blot, which also examined activation of Janus kinase 2 (JAK2) signal pathway...
  75. Pemmaraju N, Moliterno A. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. Am Soc Clin Oncol Educ Book. 2015;:139-45 pubmed publisher
  76. Sadras T, Heatley S, Kok C, Dang P, Galbraith K, McClure B, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Lett. 2017;408:92-101 pubmed publisher
  77. Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?. Leukemia. 2011;25:1059-63 pubmed publisher
  78. Lasho T, Pardanani A, Tefferi A, Smith D. Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms. Leukemia. 2014;28:1762-4 pubmed publisher
  79. Grundschober E, Hoelbl Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, et al. Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia. 2014;28:1918-22 pubmed publisher
  80. Hurtado C, Erquiaga I, Aranaz P, Miguéliz I, Garcia Delgado M, Novo F, et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. Leuk Res. 2011;35:1537-9 pubmed publisher
  81. Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica. 2010;95:1435-8 pubmed publisher
  82. Alvarez Larran A, Senín A, Fernández Rodríguez C, Pereira A, Arellano Rodrigo E, Gómez M, et al. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2017;178:764-771 pubmed publisher
    ..95 days, P = 0·003). In conclusion, CALR genotype is associated with a lower risk of leukaemic transformation. Leukaemia arising in a JAK2 V617F-negative clone is TP53 independent and shows better survival. ..
  83. Vannucchi A, Verstovsek S, Guglielmelli P, Griesshammer M, Burn T, Naim A, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96:1113-1120 pubmed publisher
    ..V617F allele burden in patients with PV who are resistant to or intolerant of hydroxyurea. The relationship between allele burden changes and clinical outcomes in patients with PV remains unclear. ..
  84. Swierczek S, Nausová J, Jelinek J, Liu E, Roda P, Kucerova J, et al. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 2013;88:157-8 pubmed publisher
  85. Zheng L, Chen J, Zhou Z, He Z. Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway. Tumour Biol. 2017;39:1010428317705335 pubmed publisher
    ..Cell viability, colony formation capacity, and phosphorylation of Janus kinase 2 and signal transducer and activator of transcription 3 in treated SGC-7901 and BGC-823 cells were detected by ..
  86. McCormick S, Higgins R, Grutkoski P, Bousquet M, Quelen C, Bartholomaus L, et al. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation. Br J Haematol. 2015;169:290-3 pubmed publisher
  87. Choe J, Park K, Park S, Lee S, Kim S. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther. 2013;15:R26 pubmed publisher
    ..These data suggest that tacrolimus might affect the RANKL expression in IL-6 stimulated FLS through STAT3 suppression, together with up-regulation of SOCS3. ..
  88. Haslam K, Molloy K, Conneally E, Langabeer S. Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Clin Chem Lab Med. 2014;52:e29-31 pubmed publisher
  89. Wang A, Zhang F, Xu H, Xu M, Cao Y, Wang C, et al. TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-?B/STAT3 pathways. Mol Immunol. 2017;87:67-75 pubmed publisher
    ..Total and phosphorylated of inhibitor-?B (I-?B), nuclear factor kappa B (NF-?B), Janus kinase 2 (JAK2), and signal transducers and activators of transcription 3 (STAT3) were examined by western blotting ..